CIK 0001690585 · Non-accelerated filer<br>Smaller reporting company
Dianthus Therapeutics, Inc. /DE/
Sign in to watch- Ticker
- DNTH
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 929-999-4055
- Business address
- 7 TIMES SQUARE, 43RD FLOOR, NEW YORK, NY, 10036
- Former names
- Magenta Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $16,043,610
- in 4 filings, $16.0M under 10b5-1 plans
Net −$16,043,610. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-08-01 | Stants Kristen Chief People Officer | Grant or award · Stock Option (Right to Buy) | +85,000 | 85,000 | ||
| 2022-08-01 | Deardorf Caren Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +75,000 | 75,000 | ||
| 2022-06-28 | Booth Bruce Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2022-06-28 | Daniel Thomas O Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2022-06-28 | Lawton Alison Frances Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2022-06-28 | RONNEBERG AMY L Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2022-06-28 | Albers Jeffrey W. Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2022-06-28 | Scadden David Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2022-06-28 | McGeorge Anne Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2022-05-31 | Stants Kristen Chief People Officer | Grant or award | +3,000 | $0.99 | $3K | 17,264 |
| 2022-05-31 | Deardorf Caren Chief Commercial Officer | Grant or award | +3,000 | $0.99 | $3K | 16,762 |
| 2022-05-31 | GARDNER JASON See Remarks | Grant or award | +3,000 | $0.99 | $3K | 289,872 |
| 2022-05-31 | Beetham Thomas W. See Remarks | Grant or award | +3,000 | $0.99 | $3K | 16,897 |
| 2022-05-17 | Olson Lisa See Remarks | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2022-05-17 | Humphrey Jeffrey Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2022-05-17 | GARDNER JASON See Remarks | Grant or award · Stock Option (Right to Buy) | +162,500 | 162,500 | ||
| 2022-05-17 | Stants Kristen Chief People Officer | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2022-05-17 | Nichols David Wayne Chief Technical Officer | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2022-05-17 | Mahoney Stephen F. See Remarks | Grant or award · Stock Option (Right to Buy) | +62,500 | 62,500 | ||
| 2022-05-17 | Beetham Thomas W. See Remarks | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 |
Page 14 of 24 · 470 trades